NEW YORK (GenomeWeb) – Seegene today announced it has established Seegene Technologies, a new US subsidiary based in Concord, Calif.
The South Korean firm said it plans to enhance its sales in the US by directly managing existing clients and gaining new ones. Seegene will also pursue several US Food and Drug Administration submissions of reagents for multiplexed tests to detect respiratory and gastrointestinal infections.
Seegene is looking to develop original design manufacturing partnerships with in vitro diagnostics firms and plans to establish a cGMP facility and a US manufacturing and supply system by 2017, the firm said in a statement.
Seegene CEO Jong-Yoon Chun said that a US subsidiary was an important step in growing the firm's global market presence.
In February, Seegene obtained its first FDA 510(k) market clearance for its TOCE-based assay to detect herpes simplex viruses 1 and 2.